title: Ipilimumab-induced hypophysitis: early Australian experience.
authors.affiliation: Department of Endocrinology, St Vincent's Hospital, Sydney, NSW, Australia. s.desousa@garvan.org.au.
authors.forename: Sunita M C
authors.initials: SM
authors.lastname: De Sousa
authors.affiliation: Melanoma Institute Australia, Sydney, NSW, Australia.
authors.forename: Georgina V
authors.initials: GV
authors.lastname: Long
authors.affiliation: Diabetes and Metabolism Division, Garvan Institute of Medical Research, Sydney, NSW, Australia.
authors.forename: Katherine T
authors.initials: KT
authors.lastname: Tonks
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001315:Australia; D018450:Disease Progression; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007018:Hypopituitarism / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D005938:Glucocorticoids; D000074324:Ipilimumab; D011239:Prednisolone